SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?


To: jerry carlson who wrote (4522)4/2/1998 12:38:00 AM
From: Rocketman  Respond to of 9719
 
March 22, 1996 -- Palo Alto, California

Incyte Pharmaceuticals, Inc. (Nasdaq: INCY) announced today the signing of an agreement with GeneTrace Systems Inc. under which Incyte will license
GeneTrace's mass spectrometry technology and collaborate with GeneTrace in the development of specific DNA analysis applications. Incyte will pay
GeneTrace R&D milestone payments, technology license fees and will acquire a minority stake in the company. Specific terms of the agreement were not
disclosed.

The rest of the press release is at:

incyte.com

By the way, Genetrace is an SRI spin-off.

INCY wants any new and potentially better sequencing technologies.

Rman